Results 51 to 60 of about 7,825 (259)

Systemic Acrolein Elevations in Mice With Experimental Autoimmune Encephalomyelitis and Patients With Multiple Sclerosis [PDF]

, 2018
Demyelination and axonal injury are the key pathological processes in multiple sclerosis (MS), driven by inflammation and oxidative stress. Acrolein, a byproduct and instigator of oxidative stress, has been demonstrated as a neurotoxin in experimental ...
Acosta, Glen, Hayward, Lee, Mattson, David, Race, Nicholas, Shi, Riyi, Tang, Jonathan, Tian, Ran, Tully, Melissa, Zheng, Lingxing   +8 more
core   +1 more source

A hypothesis for an alternative treatment for tobacco addiction: phenelzine, a monoamine oxidase inhibitor

Tobacco Induced Diseases, 2018
Background Current smoking cessation methods are primarily based on the theory that nicotine is the principal addicting compound overlooking the contribution of the monoamine oxidase inhibitors present in tobacco. Our study tests the hypothesis that the
Claude A. Curran, Roger A. Boshes, Daniel Y. Lee, Patrizia M. Coratti Curran, Beth Hott   +4 more
doaj   +1 more source

Lysine-Specific Histone Demethylase 1A Regulates Macrophage Polarization and Checkpoint Molecules in the Tumor Microenvironment of Triple-Negative Breast Cancer

Frontiers in Immunology, 2019
Macrophages play an important role in regulating the tumor microenvironment (TME). Here we show that classical (M1) macrophage polarization reduced expression of LSD1, nuclear REST corepressor 1 (CoREST), and the zinc finger protein SNAIL.
Abel H. Y. Tan, WenJuan Tu, Robert McCuaig, Kristine Hardy, Thomasina Donovan, Sofiya Tsimbalyuk, Jade K. Forwood, Sudha Rao   +7 more
doaj   +1 more source

Cognitive function and lifetime features of depression and bipolar disorder in a large population sample: Cross-sectional study of 143,828 UK Biobank participants [PDF]

, 1996
Background: This study investigated differences in cognitive performance between middle-aged adults with and without a lifetime history of mood disorder features, adjusting for a range of potential confounders.
Cullen, B., Deary, I..J., Evans, J.J., Gallacher, J., Mackay, D.F., Martin, D., McIntosh, A., Nicholl, B.I., Pell, J.P., Smith, D.J., Ul-Haq, Z.   +10 more
core   +2 more sources

Adverse psychiatric effects associated with herbal weight-loss products [PDF]

, 2015
Date of Acceptance: 02/08/2015. Copyright © 2015 F. Saverio Bersani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided ...
Bersani, Francesco Saverio, Bolzan Mariotti Posocco, Flaminia, Corazza, Ornella, Coviello, Marialuce, De Stefano, Gianfranco, Francesconi, Marta, Hough, Christina M., Imperatori, Claudio, Minichino, Amedeo, Santacroce, Rita, Valeriani, Giuseppe   +10 more
core   +3 more sources

LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials

Frontiers in Pharmacology, 2023
Histone lysine-specific demethylase 1 (LSD1/KDM1A) was first identified in 2004 as an epigenetic enzyme able to demethylate specific lysine residues of histone H3, namely H3K4me1/2 and H3K9me1/2, using FAD as the cofactor.
Beatrice Noce, Elisabetta Di Bello, Rossella Fioravanti, Antonello Mai, Antonello Mai   +4 more
doaj   +1 more source

Atypical Depression [PDF]

, 2013
Atypical depression is defined as a specifier of major depressive disorder. Columbia criteria for atypical depression are commonly used to make a diagnosis.
Ahmet Koyuncu, Erhan Ertekin, Selim Sağır, Zerrin Binbay   +3 more
core   +1 more source

Lysine-Specific Demethylase 1 Inhibitors: A Comprehensive Review Utilizing Computer-Aided Drug Design Technologies. [PDF]

Molecules
Lysine-specific demethylase 1 (LSD1/KDM1A) has emerged as a promising therapeutic target for treating various cancers (such as breast cancer, liver cancer, etc.) and other diseases (blood diseases, cardiovascular diseases, etc.), owing to its observed ...
Han D, Lu J, Fan B, Lu W, Xue Y, Wang M, Liu T, Cui S, Gao Q, Duan Y, Xu Y.   +10 more
europepmc   +2 more sources

Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database

BMC Psychiatry, 2020
Background Antidepressants-induced movement disorders are rare and imperfectly known adverse drug reactions. The risk may differ between different antidepressants and antidepressants’ classes.
Alexis Revet, François Montastruc, Anne Roussin, Jean-Philippe Raynaud, Maryse Lapeyre-Mestre, Thi Thu Ha Nguyen   +5 more
doaj   +1 more source

Treatment of Selective Mutism: Focus on Selective Serotonin Reuptake Inhibitors [PDF]

, 2008
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90271/1/phco.28.2.214 ...
Berger I, Golwyn DH, Guna-Dumitrescu L, Janice L Stumpf, Lehman RB, Murphy TK, Schwartz RH, Simons D, Stein MT, Steinhausen HC, Yaman Kaakeh   +10 more
core   +1 more source